Effects of procainamide and quinidine sulfate in the Wolff-Parkinson-White syndrome.
Thirty-three patients with Wolff-Parkinson-White syndrome were studied electrophysiologically before and after administration of intravenous procainamide and oral quinidine sulfate. Procainamide prolonged the shortest R-R (SRR) interval between two consecutive pre-excited beats during atrial fibrillation 20-70 msec in 15 of 21 patients with no change observed in 6 of 21 patients. Quinidine sulfate prolonged the SRR 20-170 msec in all 16. In 14 of 18 patients where procainamide and quinidine were comparable, quinidine prolonged the SRR 30-100 msec more than procainamide.
D001281:Atrial Fibrillation / Q000188:drug therapy / Q000503:physiopathology; D004594:Electrophysiology; D005260:Female; D006801:Humans; D008297:Male; D011342:Procainamide / Q000494:pharmacology* / Q000627:therapeutic use; D011802:Quinidine / Q000494:pharmacology* / Q000627:therapeutic use; D014927:Wolff-Parkinson-White Syndrome / Q000188:drug therapy / Q000503:physiopathology*
D011802:Quinidine; D011342:Procainamide